SMARCA5 and acute myeloid leukemia: Interestingly, in acute myeloid leukemia (AML) patients, CD34+ hematopoietic progenitors show SNF2H upregulation [248], which can be drug-inhibited to release terminal-differentiation while sparing normal hematopoiesis [249].